1-12 of 12
Anna Lysen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Frida Bugge Bugge Askeland, Einar Haukås, Tobias S. S. Slørdahl, Anja Klostergaard, Tatjana Alexandersen, Anna Lysén, Pegah Abdollahi, Emil Hermansen, Fredrik Schjesvold
Journal: Blood
Blood (2024) 144 (Supplement 1): 4730.
https://doi.org/10.1182/blood-2024-193864
Published: 2024
Journal Articles

Krd Consolidation Abrogates Poor Prognosis of FDG PET/CT Positivity after ASCT: Results from a Phase II Study (CONPET)

Jakob Nordberg Nørgaard, Anna Lysén, Galina Tsykunova, Annette Vangsted, Cristina João, Nora Remen, Lene Kongsgaard Nielsen, Caroline Stokke, James P Connelly, Mona-Elisabeth R. Revheim, Fredrik Schjesvold
Journal: Blood
Blood (2024) 144 (Supplement 1): 4745.
https://doi.org/10.1182/blood-2024-198925
Published: 2024
Journal Articles

A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group

Diana Loigom, Tobias S. S. Slørdahl, Anna Lysén, Agoston Gyula Szabo, Tine Rosenberg, Lene Kongsgaard Nielsen, Jakub Krejcik, Anne Marit Sponaas, Kristine Misund, Nicolai Jacob Wewer Albrechtsen, Jakob Nordberg Nørgaard, Thomas Lund, Sarah Leeth Hansen Farmer, Einar Haukås, Kari Lenita Falck Moore, Tatjana Tratš, Claire Albrecht, Diptendu Santra, Pavel Smirnov, Margaret Doyle, Kathleen S Gray, Fredrik Schjesvold
Journal: Blood
Blood (2024) 144 (Supplement 1): 7016.
https://doi.org/10.1182/blood-2024-203364
Published: 2024
Journal Articles

Vaccinating Against Mutated RAS in Multiple Myeloma: The Phase I/II TG01/QS-21 Study

Hanne Marie Norseth, Hedda Berg Monsen, Nora Remen, Else Marit Inderberg, Helen Vålerhaugen, Laila Helene Bergly, Anna Lysén, Ingerid Weum Abrahamsen, Fredrik Schjesvold
Journal: Blood
Blood (2024) 144 (Supplement 1): 7053.
https://doi.org/10.1182/blood-2024-198229
Published: 2024
Journal Articles

Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study

Frida Bugge Askeland, Anne-Marie Rasmussen, Anna Lysen, Einar Haukås, Anette Løken Eilertsen, Magnus Moksnes, Galina Tsykunova, Anders Vik, Birgitte Dahl Eiken, Vidar Stavseth, Jürgen Rolke, Eivind Ottersen Samstad, Valdas Peceliunas, Randi Fykse Hallstensen, Ariane Aasbø Hansen, Anita Smith Nilsen, Tobias S. Slørdahl, Fredrik Schjesvold
Journal: Blood
Blood (2023) 142 (Supplement 1): 4755.
https://doi.org/10.1182/blood-2023-189022
Published: 2023
Journal Articles

Upfront Autologous Stem Cell Transplantation in Myeloma Patients >65 Years: A Population-Based Study from the Nordic Myeloma Study Group

Kari Lenita Falck Moore, Anna Genell, Ain Kaare, Dorota Knut-Bojanowska, Diana Loigom, Anna Lysen, Jakob Nordberg Nørgaard, Katrin Palk, Maris Pärnat, Valdas Peceliunas, Sæmundur Rögnvaldsson, Fredrik Schjesvold, Alexander Sigurdsson, Agoston Gyula Szabo, Jonathan Thorsen, Sigrun Thorsteinsdottir, Vilmantė Vaitekėnaitė, Annette J. Vangsted, Cecilie Hveding Blimark
Journal: Blood
Blood (2023) 142 (Supplement 1): 4729.
https://doi.org/10.1182/blood-2023-172546
Published: 2023
Journal Articles

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Frida Bugge Askeland, Einar Haukås, Tobias S. Slørdahl, Anja Klostergaard, Tatjana Alexandersen, Diana Schjøll, Anna Lysen, Emil Hermansen, Fredrik Schjesvold
Journal: Blood
Blood (2023) 142 (Supplement 1): 3381.
https://doi.org/10.1182/blood-2023-173126
Published: 2023
Journal Articles

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Frida Bugge Bugge Askeland, Einar Haukås, Tobias S. Slørdahl, Diana Schjøll, Anna Lysén, Emil Hermansen, Fredrik Schjesvold
Journal: Blood
Blood (2022) 140 (Supplement 1): 12623–12625.
https://doi.org/10.1182/blood-2022-156625
Published: 2022
Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET)

Jakob Nordberg Nørgaard, Niels Abildgaard, Anna Lysén, Galina Tsykunova, Annette Juul Vangsted, Cristina João, Nora Remen, James P Connelly, Mona-Elisabeth R. Revheim, Fredrik H. Schjesvold
Journal: Blood
Blood (2021) 138 (Supplement 1): 3939.
https://doi.org/10.1182/blood-2021-147240
Published: 2021
Journal Articles

Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)

Jakob Nordberg Nørgaard, MD, Niels Abildgaard, MD, Anna Lysén, MSc, Mona-Elisabeth R Revheim, MD PhD, James P Connelly, MD PhD, Fredrik H. Schjesvold, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3172.
https://doi.org/10.1182/blood-2019-125523
Published: 2019
Journal Articles

Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway

Fredrik H. Schjesvold, MD PhD, Anderson Jenna, Jaak Sõnajalg, Amy Leval, PhD, Anna Lysén, MSc, Saeeda Rana, Päivi Castren-Kortekangas, Fredrik Borgsten
Journal: Blood
Blood (2018) 132 (Supplement 1): 5759.
https://doi.org/10.1182/blood-2018-99-114474
Published: 2018
Journal Articles

Carfilzomib-Based Regimens Are Efficacious and Well Tolerated in Heavily Pre-Treated Multiple Myeloma Patients: Real World Data from a Norwegian Cohort

Anna Lysén, MSc, Ina Haarstad, MDcal student, Fredrik H. Schjesvold, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5651.
https://doi.org/10.1182/blood-2018-99-110364
Published: 2018